Depressive Symptom clinical trials

Explore recruiting depressive symptom clinical trials.

Recruiting depressive symptom studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Depressive Symptom trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

ERPPAD - Efficacy in Relapse Prevention: Psilocybin in Alcohol use disorder with Depressive symptoms

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A prospective randomized, single blind, controlled, safety and non-inferiority study of esketamine plus propofol compared to methohexital anesthesia for electroconvulsive therapy

Austria

Phase III and phase IV (Integrated) EU CTIS Study details

Efficacy of Ketamine for the Prevention of Relapse in Patients with Opioid-Use Disorders (OUD)

Cyprus

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomized, double-blind, placebo-controlled trial of the efficacy and safety of tianeptine in the treatment of covid fog symptoms in patients after COVID-19 with the study of the pathophysiology of the phenomenon using positron emission tomography, biochemical, immunological and electrophysiological parameters (COVMENT).

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

RESET-TRD; a Randomised trial on oral ESketamine compared to Electroconvulsive Therapy for patients with Treatment Resistant Depression

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

KET01-IIT03: A Pilot, Open-label Phase II Trial of Adjunctive Treatment with Ketamine Hydrochloride Prolonged-Release Tablets (KET01) during the Initiation of Antidepressant Therapy in Major Depressive Disorder

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

Depressive Symptom trials by city

Depressive Symptom in Toronto Depressive Symptom in Vancouver Depressive Symptom in Montreal Depressive Symptom in Calgary Depressive Symptom in Edmonton Depressive Symptom in Ottawa Depressive Symptom in Winnipeg Depressive Symptom in Quebec City Depressive Symptom in Hamilton Depressive Symptom in Kitchener Depressive Symptom in London Depressive Symptom in Halifax Depressive Symptom in New York Depressive Symptom in Los Angeles Depressive Symptom in Chicago Depressive Symptom in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease